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Abstract: Snakebite envenomation causes over 140,000 deaths every year, predominantly in
developing countries. As a result, it is one of the most lethal neglected tropical diseases. It is
associated with incredibly complex pathophysiology due to the vast number of unique toxins/proteins
present in the venoms of diverse snake species found worldwide. Here, we report the purification and
functional characteristics of a Group I (PI) metalloprotease (CAMP-2) from the venom of the western
diamondback rattlesnake, Crotalus atrox. Its sensitivity to matrix metalloprotease inhibitors (batimastat
and marimastat) was established using specific in vitro experiments and in silico molecular docking
analysis. CAMP-2 shows high sequence homology to atroxase from the venom of Crotalus atrox and
exhibits collagenolytic, fibrinogenolytic and mild haemolytic activities. It exerts a mild inhibitory
effect on agonist-induced platelet aggregation in the absence of plasma proteins. Its collagenolytic
activity is completely inhibited by batimastat and marimastat. Zinc chloride also inhibits the
collagenolytic activity of CAMP-2 by around 75% at 50 µM, while it is partially potentiated by calcium
chloride. Molecular docking studies have demonstrated that batimastat and marimastat are able to
bind strongly to the active site residues of CAMP-2. This study demonstrates the impact of matrix
metalloprotease inhibitors in the modulation of a purified, Group I metalloprotease activities in
comparison to the whole venom. By improving our understanding of snake venom metalloproteases
and their sensitivity to small molecule inhibitors, we can begin to develop novel and improved
treatment strategies for snakebites.
Keywords: Crotalus atrox; metalloprotease; snake venom; neglected tropical disease; rattlesnake;
batimastat; marimastat; antivenom
Key Contribution: This study details the purification of a Group I (PI) snake venom metalloprotease
(SVMP) from the venom of Crotalus atrox venom and the efficacy of various proposed inhibitors on this
isolated SVMP in comparison to the whole venom. Both batimastat and marimastat, commercially
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available matrix metalloprotease inhibitors, effectively abrogate the metalloprotease activity of the
isolated SVMP and whole venom.
1. Introduction
In 2017, snakebite envenomation (SBE) was reinstated to the list of neglected tropical diseases
by the World Health Organisation [1,2]. SBE is estimated to occur in at least 1.8–2.7 million people,
resulting in around 80,000–137,000 deaths and over 400,000 amputations worldwide per year [3].
The distribution of fatalities is primarily concentrated in rural tropical areas that are some of the world’s
poorest and most healthcare deprived communities [1,4,5]. Prompt access to antivenom therapy and
appropriate medical facilities is crucial in order to protect victims from death, potential extensive
limb injuries and the possibility of subsequent, long-term disabilities [4]. The current antivenoms
are considered to be sub-optimal in preventing venom-induced tissue damage due to their inability
to access the affected local tissues [4,5]. Hence, the development of small molecules that are able to
neutralise the locally acting venom components would be highly beneficial in treating SBE, specifically
SBE-induced muscle damage and/or tissue necrosis.
Snake venoms are a complex mixture of bioactive proteins and peptides that have evolved over
time to assist in subduing and killing prey as quickly as possible, as well as having a secondary role
in prey digestion and defence [5]. The clinical effects of SBE range from mild local reactions to more
serious life-threatening conditions depending on a variety of variables including the size, species and
locality of the snake [6,7], ontogeny [8,9], body mass and health of the victim and the total volume of
venom injected [1,10]. Snake venoms are composed of both enzymatic and non-enzymatic components.
The enzymatic components of viper venoms primarily include the snake venom metalloproteases
(SVMPs), serine proteases and phospholipase A2 (PLA2), whereas non-enzymatic venom components
include three-finger toxins, C-type lectins and disintegrins amongst many others [5]. The western
diamondback rattlesnake, Crotalus atrox (C. atrox) is likely to be responsible for the majority of
SBE-induced fatalities in Northern Mexico [11]. C. atrox venom has an abundance of two major protein
families, SVMPs and serine proteases, which together account for approximately 70% of the total
protein found within the venom [12].
SVMPs are zinc-dependent enzymes that vary in molecular mass from approximately 20 to
100 kDa and are responsible for the haemorrhagic effects and local tissue damage frequently seen
upon viper envenomation [13,14]. SVMPs are classified into PI to PIV depending on the presence of
additional domains [15]: PI—only a metalloprotease domain; PII—a metalloprotease and a disintegrin
domain; PIII—a metalloprotease domain, a disintegrin-like and a cysteine-rich domain; PIV—two
C-type lectin domains in addition to all the domains present in PIII. SVMPs are involved in a wide range
of toxic activities, including the degradation of collagen and other basement membrane components,
fibrinogen and a range of other proteins [13]. The peptidomimetic molecules, batimastat and marimastat
are broad-spectrum matrix metalloprotease (MMPs) inhibitors [16] that have been proposed as next
generation treatment options for the SVMP-induced effects of SBE [17]. This inhibition is achieved
by mimicking the cleavage site of natural substrates and binding to the zinc ion found in the active
site of these proteases. In this way, batimastat and the orally bioavailable and similar compound,
marimastat are able to inhibit both matrix metalloproteases as well as SVMPs [5]. An improved
understanding of MMPs, their inhibitors, and their relationship with SVMPs will aid in the development
of improved therapeutic strategies for SBE.
SVMPs in C. atrox venom account for 49.7% of total venom, which breaks down further to 22.4% PI
and 27.3% PIII SVMPs [12]. In order to determine the therapeutic potential of batimastat and marimastat
against PI venom metalloproteases, here, we report the purification and functional characterisation of a
PI metalloprotease with a molecular weight of around 23 kDa from the venom of C. atrox. The sensitivity
of the purified protein to inhibition by batimastat and marimastat was established in comparison to the
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whole C. atrox venom. Together, this study supports the potential beneficial effects of these molecules
against the broad spectrum of pathological effects induced by SVMPs.
2. Results
2.1. Purification and Identification of CAMP-2
To purify a PI SVMP from the venom of C. atrox, we deployed a two-dimensional chromatography
approach. Initially, 50 mg of whole C. atrox venom was applied to a cation-exchange (SP-HP)
chromatography column (Figure 1A) followed by the analysis of collected fractions using SDS-PAGE
(Figure 1B). Due to the abundance of the target protein at a molecular weight of around 23 kDa (typical
for a PI SVMP [18]), the selected fractions (6–9) were further fractionated by gel filtration (Superdex 75,
1.6 × 70 cm) chromatography (Figure 1C). Following SDS-PAGE analysis (Figure 1D), selected fractions
(67–72) were further run through the same gel filtration column to remove any impurities from the
protein of interest (Figure 1E,F). Finally, a pure protein with a molecular weight of approximately
23 kDa was isolated, which we henceforth refer to as CAMP-2 (denoting the second SVMP that we have
isolated from the venom of C. atrox). The molecular weight of the isolated protein was confirmed under
native conditions using chymotrypsinogen A (25 kDa) as a marker in gel filtration chromatography
(indicated with an arrow in Figure 1C,E) and under denaturing (reduced) conditions using SDS-PAGE
(Figure 1F).Toxins 2020, 12, x FOR PEER REVIEW 4 of 18 
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(E) indicates the position of chymotrypsinogen A (25 kDa), which was used as a molecular weight 
marker in the same gel filtration column. (G) Tryptic digested peptides of the purified protein were 
analysed by mass spectrometry and the data show 52.2% identity to a previously sequenced PI SVMP, 
atroxase, from C. atrox venom. The mass spectrometry-identified peptide sequences of purified 
protein are shown in yellow on the sequence of atroxase. 
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using a cation exchange chromatography column (A) And the collected fractions were analysed by
SDS-PAGE (B). (C) A chromatogram showing the gel filtration chromatography profile of fractions 6 to
9 collected from the cation exchange column. (D) SDS-PAGE analysis of selected fractions resulting
from the gel filtration chromatography. (E) The chromatogram from the second run of gel filtration
chromatography using fractions 67–72 from the previous run, and SDS-PAGE analysis showing the
purified protein (F). The gels shown were stained with Coomassie brilliant blue. The arrow in (C) and
(E) indicates the position of chymotrypsinogen A (25 kDa), which was used as a molecular weight
marker in the same gel filtration column. (G) Tryptic digested peptides of the purified protein were
analysed by mass spectrometry and the data show 52.2% identity to a previously sequenced PI SVMP,
atroxase, from C. atrox venom. The mass spectrometry-identified peptide sequences of purified protein
are shown in yellow on the sequence of atroxase.
To determine the identity of the purified protein, it was subjected to trypsin digestion and
subsequent analysis by mass spectrometry (Figure 1G). Mascot analysis of the MS/MS data suggested
that the isolated protein possesses a high sequence identity to atroxase, a 23 kDa SVMP from the
venom of C. atrox [19,20]. The peptide sequences resulting from the mass spectrometry covered
52.2% of atroxase, suggesting that the purified protein is highly likely to be atroxase although we
cannot confirm this due to the lack of complete sequencing from this study. However, these data
confirm that the purified protein is a PI SVMP with a molecular weight of 23 kDa, and it is likely to
be atroxase, which was previously purified and characterised as a non-haemorrhagic protease with
fibrin(ogen)olytic activities [20–23].
2.2. CAMP-2 Exerts Collagenolytic, Fibrinogenolytic and Haemolytic Activities
To determine the roles of CAMP-2, various functional assays using synthetic and natural substrates
were performed in comparison to the whole C. atrox venom. Fluorogenic substrates such as DQ-gelatin
and EnzCheckTM lipid-based substrate were used to assess if CAMP-2 possesses metalloprotease
(collagenolytic) and PLA2 activities, respectively. Similar to the whole C. atrox venom (Figure 2A),
CAMP-2 (Figure 2B) exhibited strong collagenolytic activity. While the whole C. atrox venom showed
clear PLA2 activity, CAMP-2 did not display any PLA2 activity (Figure 2C). These data not only suggest
that CAMP-2 is an SVMP, but it is also free from any PLA2 impurities which have a similar molecular
weight. Moreover, human fibrinogen, a plasma protein which is a natural substrate for some SVMPs,
was incubated with CAMP-2, before the digest was analysed by SDS-PAGE to determine its effects
on fibrinogen. This analysis showed that CAMP-2 has fibrinogenolytic activity and notably, it exerts
high specificity for the Aα chain of fibrinogen, as it was completely digested within 10 min (Figure 2D)
although over a longer time (e.g., 12 h), it also began to degrade the Bβ chain while the γ chain of
fibrinogen remained largely unaffected. Similarly, CAMP-2 showed a mild haemolytic effect compared
to the whole venom when incubated with human red blood cells over 24 h (Figure 2E). These data
suggest that CAMP-2 is a collagenolytic, fibrinogenolytic and mildly haemolytic enzyme.
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Figure 2. Functional characterisation of CAMP-2. The metalloprotease (collagenolytic) activity of
different concentrations of whole C. atrox venom (A) and CAMP-2 (B) was assessed using DQ gelatin
(a fluorogenic substrate). (C) the PLA2 activity of whole C. atrox venom and CAMP-2 was analysed
using EnzCheckTM lipid-based substrate. (D) The fibrinogenolytic activity of CAMP-2 was analysed
by incubating it with human fibrinogen and the samples collected at different time points (0–720 min as
indicated at the top) were assessed by SDS-PAGE and Coo assie staining. (E) Haemolytic activity
of whole C. atrox venom and CAMP-2 was analysed by incubating them with human red blood cells
and analysing the cell-free supernatant by spectrometry. The positive (+ve) control represents the
complete lysis achieved using 1% (v/v) Triton-X in PBS. Data represent mean ± S.D. (n = 3). The p-values
shown were calculated using one-way ANOVA followed by posthoc Tukey’s test using GraphPad
Prism (** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001).
2.3. CAMP-2 Inhibits Human Platelet Aggregation
To determine if CAMP-2 is able to affect human platelet function, platelet aggregation assays using
platelet-rich plasma (PRP) and isolated platelets from human whole blood were used. CAMP-2 at
both low (3 µg/mL) and high (10 µg/mL) concentrations did not induce platelet aggregation on its
own (indicated as 0–5 min in aggregation traces shown in Figure 3). However, 10 µg/mL CAMP-2
inhibited (Figure 3A,B) platelet aggregation (by around 25%) induced by a cross-linked collagen-related
peptide (CRP-XL) when isolated platelets were used, although the low concentration did not show
any significant effect. This inhibitory effect was absent when PRP (i.e., in the presence of plasma
proteins) was used (Figure 3C,D). When the whole C. atrox venom was used, at a low concentration
(3 µg/mL) it displayed mild inhibitory effects on CRP-XL induced platelet aggregation, although at a
higher (10 µg/mL) concentration it has possibly lysed (even in the absence of an agonist as shown in
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the aggregation traces between 0 and 5 minutes) the platelets when both isolated platelets (Figure 3E,F)
and PRP (Figure 3G,H) were used. These results demonstrate that although CAMP-2 is able to display
a minimal inhibitory effect on platelet aggregation when isolated platelets were used, it is unable to
affect their function in the presence of plasma proteins, indicating that this may not be its primary role
in humans. However, the whole venom may induce the lysis of platelets based on the concentrations
injected during the bite.Toxins 2020, 12, x FOR PEER REVIEW 7 of 18 
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Figure 3. Effect of CAMP-2 on human platele s. The eff ct of CAM an isolated pla elets (A,B)
and platelet-rich plasma (PRP) (C,D) was analysed in the presence and absence of a platelet agonist,
cross-linked collagen-related peptide (CRP-XL) by aggregometry. Similar experiments using isolated
platelets (E,F) and PRP (G,H) were performed using the whole C. atrox venom. The aggregation traces
shown are representative of three separate experiments. (I) The cytotoxicity of CAMP-2 and the whole
venom was determined by in ubating them with human platelets for 30 min and analysing using a
lactate dehydrogenase (LDH) assay kit by spectrometry. The positive (+ve) control (100% cytotoxicity)
was achieved using a lysis buffer provided in the kit. Data represent mean ± S.D. (n = 3). The p-values
shown were calculated using one-way ANOVA followed by a posthoc Tukey’s test using GraphPad
Prism (* p ≤ 0.05, ** p ≤ 0.01, and **** p ≤ 0.0001).
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In order to assess if CAMP-2 and the whole venom are able to exert direct cytotoxic effects
on platelets, lactate dehydrogenase (LDH) assay using human isolated platelets was performed.
These results indicated that CAMP-2 does not have any cytotoxic effects on platelets at the concentrations
tested in this study, although the whole venom displayed a mild (around 10% at 10 µg/mL) cytotoxic
effect on platelets (Figure 3I) similar to its effect on platelet aggregation (Figure 3E–H).
2.4. Chlorides and a Metal Chelator Affect Metalloprotease Activity of CAMP-2
As zinc-dependent proteases, SVMPs rely on free divalent cations such as calcium for catalysis,
the impact of various metal chlorides on the metalloprotease activity of CAMP-2 was assessed.
Diverse concentrations of both zinc and calcium chloride were used to assess if they would interfere
with the metalloprotease (collagenolytic) activity of CAMP-2 and the whole C. atrox venom. The results
demonstrate that while zinc chloride significantly reduced the metalloprotease activity observed with
both the whole venom (Figure 4A) and CAMP-2 (Figure 4B), calcium chloride potentiated this activity
of whole venom (Figure 4C) and CAMP-2 (Figure 4D).
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Figure 4. The effect of chlorides and a metal chelator on the metalloprotease activity of CAMP-2.
The effect of different concentrations of zin loride on th metalloprote s (collagenolytic) activity of
whole venom (A) and CAMP-2 (B) was analysed using DQ-gelatin as a substrate by spectrofluorimetry.
Similarly, the effect of various concentrations of calcium chloride (C,D) and a metal chelator, EDTA (E,F)
on whole C. atrox venom, as well as on CAMP-2, was analysed. Data represent mean ± S.D. (n = 3).
The p-values shown are as calculated by one-way ANOVA followed by posthoc Tukey’s test using
GraphPad Prism (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001).
Similarly, the effect of a metal chelator on proteolytic activity was assessed using
ethylenediaminetetraacetic acid (EDTA). The metalloprotease activity of both whole venom (Figure 4E)
and CAMP-2 (Figure 4F) was strongly inhibited by different concentrations of EDTA, further
corroborating that CAMP-2 is a metalloprotease and sensitive to metal chelators such as EDTA.
Toxins 2020, 12, 309 8 of 17
2.5. Marimastat and Batimastat Inhibit the Activity of CAMP-2
After confirming the biological actions of CAMP-2, the effects of MMP inhibitors, batimastat and
marimastat on this protein in comparison to the whole C. atrox venom were analysed.
Different concentrations of these inhibitors were incubated with 2 µg of CAMP-2 or whole venom
for 5 min prior to analysing their metalloprotease (collagenolytic) activity using DQ-gelatin by
spectrofluorimetry. The results suggest that marimastat (Figure 5A,B) and batimastat (Figure 5C,D) are
able to inhibit the metalloprotease activity of both the whole venom and CAMP-2. A concentration
of around 3 µM was able to completely inhibit the activity of both the whole venom and CAMP-2.
Moreover, neither marimastat nor batimastat exerted any cytotoxic effects on human platelets, as
analysed by an LDH assay (Figure 5E,F). These data suggest that these two MMP inhibitors are effective
at inhibiting PI SVMPs such as CAMP-2, and they do not possess any cytotoxic activities.
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and whole C. atrox venom. The inhibitory effects of various concentrations of marimastat (on whole
C. atrox venom (A) or CAMP-2 (B)) and batimastat (on whole C. atrox venom (C) or CAMP-2 (D)) were
quantified in vitro using a fluorogenic substrate, DQ-gelatin by spectrofluorimetry. The inhibitors
were incubated with the whole venom or CAMP-2 for 5 min prior to the addition of DQ-gelatin
and further incubation of 30 min prior to measuring the level of fluorescence by spectrofluorimetry.
The cytotoxicity of marimastat (E) and batimastat (F) on human platelets was also assessed using a
lactate dehydrogenase (LDH) assay. C represents the positive control (100% lysis) achieved using the
lysis buffer provided in the kit. Data represent mean ± S.D. (n = 3). The p-values shown are as calculated
by one-way ANOVA followed by posthoc Tukey’s test using GraphPad Prism (**** p ≤ 0.0001).
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2.6. Interactions of CAMP-2 with Batimastat and Marimastat
The mass spectrometry (Figure 1G) and functional data suggested that CAMP-2 is highly likely to
be a previously characterised PI SVMP, atroxase, from the venom of C. atrox. Hence, we have used
the complete sequence of atroxase (Uniprot accession number: Q91401) as CAMP-2 in this study for
further analysis. Sequence analysis confirmed that CAMP-2 displayed approximately 74% and 50%
identity with other metalloproteases, atrolysin C (PI SVMP; PDB accession numbers: 1DTH and 1ATL)
and catrocollastatin (PIII SVMP; PDB accession number: 2DW0), respectively, from the same C. atrox
venom. A three-dimensional structure of CAMP-2 was generated using homology modeling in Swiss
Model Server [24] based on the template of adamalysin II (PDB accession number: 4AIG) from the
venom of Crotalus adamanteus. A pairwise sequence alignment confirmed that CAMP-2 exhibited
83% identity with adamalysin II and, therefore, this protein has been used as a template instead of
atrolysin C to develop the structure of CAMP-2. The superimposing of CAMP-2 with the structure of
adamalysin has displayed a minimum rmsd of 0.142 Å, which further emphasises the reliability of
this model.
Following the validation of the modeled structure of CAMP-2, molecular docking analysis
was performed using AutoDock 4.2 [25] with the chemical structures (obtained from PubChem)
of batimastat and marimastat. Three-dimensional atomic coordinates of these compounds were
generated using the Online SMILES Translator and Structure File Generator (NCI NIH server (https:
//cactus.nci.nih.gov/translate/)). Subsequently, the compounds were subjected to energy-minimization
using the PRODRG server. The docking analysis revealed that both the inhibitors exhibited comparable
binding energy and reliable hydrogen bond interactions with the active site residues of CAMP-2 (Table 1).
While batimastat possessed slightly higher binding energy and inhibitory constant, marimastat formed
a greater number of hydrogen bonds and hydrophobic interactions with CAMP-2 (Figure 6A–D).
Notably, batimastat was found to interact with one of the catalytic triad residues, His 154, through its
backbone nitrogen, while marimastat formed a bifurcated hydrogen bond interaction with the active
site, Glu 145, through its sidechain oxygen (Table 1). These results are in line with the inhibitory effects
observed in the metalloprotease assay (Figure 5A–D).Toxins 2020, 12, x FOR PEER REVIEW 11 of 18 
 
 
Figure 6. Interactions of marimastat and batimastat with the modeled structure of CAMP-2. The 
structure of CAMP-2 was modeled using the crystal structure of adamalysin II, a highly (83%) similar 
SVMP from the venom of Crotalus adamanteus as a template. This structure was used for molecular 
docking analysis (using AutoDock) to evaluate the interactions of marimastat (A,B) and batimastat 
(C,D) with CAMP-2. The structures shown in B and D are enlarged views of the docking complex 
(catalytic site with the small molecule inhibitors batimastat and marimastat). 
3. Discussion 
Common effects of SBE caused by vipers include haemorrhage, rhabdomyolysis, oedema and 
severe muscle damage, and often these result in permanent disabilities [1]. These consequences can 
trigger serious lifestyle and socio-economic ramifications for victims, particularly those in rural areas 
with difficulty in accessing affordable and effective antivenom [26,27]. The most abundant proteins 
within viper venoms that are responsible for many of these consequences are SVMPs [13]. The 
currently used antivenom therapy has proven to be largely ineffective in treating local tissue damage 
induced by SVMPs due to their inability to access the damaged site because of the large size of 
antibodies and damaged/blocked blood capillaries around the bite site [5]. As a result, clinicians are 
forced to employ surgical procedures such as fasciotomy, debridement or limb amputation in severe 
cases to treat/remove the affected tissues [27]. Therefore, developing an alternative therapy is critical 
to prevent/treat SBE-induced muscle damage and subsequent disabilities. The use of MMP inhibitors 
such as batimastat and marimastat has been proposed to inhibit the activities of SVMPs from various 
venoms [5]. These drugs were originally developed for cancer but failed in clinical trials—batimastat 
due to its poor solubility and low oral bioavailability, and marimastat, although it showed much 
promise and reached phase II and III clinical trials, was eventually discontinued after failing to 
demonstrate a survival benefit [28]. Its longer-term use also leads to debilitating “musculoskeletal 
syndrome” [29]. Despite these failings, their applications (particularly, orally bioavailable 
marimastat) in treating the acute local effects induced by SBE would be greatly beneficial to prevent 
SBE-induced disabilities. Hence, in this study, we have evaluated the efficacy of batimastat and 
marimastat, specifically on a purified PI SVMP from the venom of C. atrox.  
Figure 6. Interactions of marimastat and batimastat with the modeled structure of CAMP-2.
The structure of CAMP-2 was eled using the crys al structure of adamalysin II, highly (83%)
similar SVMP from the venom of Crotalus adamanteus as a template. This structure was used for
molecular docking analysis (using AutoDock) to evaluate the interactions of marimastat (A,B) and
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Toxins 2020, 12, 309 10 of 17
Table 1. Results of molecular docking of CAMP-2 with the inhibitors batimastat and marimastat using
AutoDock (a molecular docking tool).
Compound Binding Energy(kcal/mol)
Ligand Efficiency
(kcal/mol)
Inhibitory Constant
(µM)
H Bond Interactions
(D-H . . . A)
Distance
(Å)
Batimastat −5.59 −0.17 79.37 ALA 114 N-H . . . OHIS 154 N-H . . . O
2.8
2.8
Marimastat −5.29 −0.23 132.52
N-H . . . O LYS 109
ILE 111 N-H . . . O
GLY 112 N-H . . . O
N-H . . . O(E2) GLU 145
O-H . . . O(E2) GLU 145
3.2
3.2
3.0
2.6
3.1
3. Discussion
Common effects of SBE caused by vipers include haemorrhage, rhabdomyolysis, oedema and
severe muscle damage, and often these result in permanent disabilities [1]. These consequences can
trigger serious lifestyle and socio-economic ramifications for victims, particularly those in rural areas
with difficulty in accessing affordable and effective antivenom [26,27]. The most abundant proteins
within viper venoms that are responsible for many of these consequences are SVMPs [13]. The currently
used antivenom therapy has proven to be largely ineffective in treating local tissue damage induced
by SVMPs due to their inability to access the damaged site because of the large size of antibodies
and damaged/blocked blood capillaries around the bite site [5]. As a result, clinicians are forced to
employ surgical procedures such as fasciotomy, debridement or limb amputation in severe cases
to treat/remove the affected tissues [27]. Therefore, developing an alternative therapy is critical to
prevent/treat SBE-induced muscle damage and subsequent disabilities. The use of MMP inhibitors
such as batimastat and marimastat has been proposed to inhibit the activities of SVMPs from various
venoms [5]. These drugs were originally developed for cancer but failed in clinical trials—batimastat
due to its poor solubility and low oral bioavailability, and marimastat, although it showed much promise
and reached phase II and III clinical trials, was eventually discontinued after failing to demonstrate a
survival benefit [28]. Its longer-term use also leads to debilitating “musculoskeletal syndrome” [29].
Despite these failings, their applications (particularly, orally bioavailable marimastat) in treating the
acute local effects induced by SBE would be greatly beneficial to prevent SBE-induced disabilities.
Hence, in this study, we have evaluated the efficacy of batimastat and marimastat, specifically on a
purified PI SVMP from the venom of C. atrox.
We have previously used the two-dimensional chromatography approach (e.g., a combination of
ion exchange and gel filtration) as an effective method to purify various venom components, including a
50 kDa PIII SVMP CAMP from the venom of C. atrox [14,30]. Here, we have deployed a similar
approach to purify a PI SVMP with a molecular weight of 23 kDa from the venom C. atrox. The mass
spectrometry analysis of this purified protein (entitled CAMP-2) suggests that this is highly likely to be
a previously sequenced protein, atroxase, from the same venom. Further functional assays confirmed
that CAMP-2 is a collagenolytic, fibrinogenolytic and mildly haemolytic enzyme. At a relatively high
concentration, CAMP-2 was also found to inhibit human platelet aggregation. These functions of
CAMP-2 are very similar to the ones that have been reported for atroxase (a non-haemolytic protease
with fibrin(ogen)olytic activity) [20,23]. Although the complete sequence of CAMP-2 was not obtained
in this study, based on the mass spectrometry and functional data, this protein is highly similar, if not
identical, to atroxase.
Given that SVMPs directly and indirectly mediate local tissue damage, the inhibition of these
enzymes is likely to reduce SBE-induced local tissue damage [13]. Here, the sensitivity of CAMP-2 to
MMP inhibitors (batimastat and marimastat) was tested in comparison to the whole C. atrox venom.
There is a great degree of both structural and functional homology between SVMPs and human variants
of MMPs [31]. This implies that substrate/inhibitor interactions between these subfamilies are likely to
be similar [31]. Marimastat is a hydroxamic acid derivative which exerts broad-range metalloprotease
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inhibition by mimicking the cleavage site of collagen substrates [31]. When comparing the structural
differences between these two compounds, marimastat has an additional hydroxyl group, increasing its
hydrophilicity and thus, improving its pharmacokinetic properties [32]. Although they are likely to
inhibit the majority of SVMPs, the additional domains found in PII, PIII, and PIV SVMPs would most
likely be unaffected by these inhibitors. Indeed, batimastat and marimastat have already been reported
to inhibit SVMPs in various venoms under in vitro and in vivo [33–35] settings. Similar to previous
studies, the metalloprotease activity of both whole venom and CAMP-2 were almost completely
inhibited by MMP inhibitors at around 3 µM. Notably, as a PI SVMP, CAMP-2 possesses only the
metalloprotease domain. These data emphasise that batimastat and marimastat are both likely to act
as broad-spectrum inhibitors for SVMPs including the PI SVMP analysed in this study. In contrast to
these inhibitors, which target only the metalloprotease domain of SVMPs, antivenoms, on the other
hand, are probably capable of binding all, or many of, the domains including the metalloprotease
domain in SVMPs. While the large size of antibodies affects their ability to reach the bite site in time
to prevent local tissue damage, the small molecule inhibitors are likely to reach and act rapidly for
SBE-induced tissue damage. Multiple injections of these inhibitors have also been suggested to treat
SBE, although the consequences of inhibiting human MMPs in the body are yet to be elucidated.
In the past, EDTA has been used to treat SBE under clinical/in vivo settings [36]. As a chelating
agent, it binds to divalent cations and therefore affects the catalytic activity of metalloproteases.
Several studies have reported the impact of EDTA on venom and other human metalloprotease
activities [36]. In this study, EDTA has inhibited the metalloprotease activity of both the venom and
CAMP-2; however, its use is problematic, and being orally bioavailable, marimastat is a far better clinical
approach, especially considering the passing of stage II clinical trials. Similarly, ZnCl2 has proven to be
a successful inhibitor of SVMPs through its ability to cause stereochemical and structural instabilities
of metalloproteases when used in excess [37,38]. ZnCl2 has also shown a significant inhibitory
effect on the metalloprotease activity of whole venom and CAMP-2 at many of the concentrations
tested. Another observation is that the plateau of the SVMP activity observed at 25, 50 and 100 µM
concentrations when the whole venom was used. This may be as a result of Zn2+ saturation, which may
have caused Zn2+ to bind to other ions and proteins within the whole venom, rather than just the
metalloproteases [39].
As marimastat and batimastat have proven to be effective in the inhibition of SVMP activity of
CAMP-2, a cytotoxicity assay was completed to establish whether they are cytotoxic to human cells,
such as platelets. As the LDH cytotoxicity assay measures whether the plasma membrane is damaged,
this can be correlated with the effects that the compounds would have on other cells in the human
body. If they present signs of cytotoxicity, they would not be appropriate for human use. However,
both marimastat and batimastat showed no significant cytotoxic effects on platelets at the numerous
concentrations tested and also passed phase I safety trials in humans [28]. This highlights their potential
for further development into next-generation treatments for SBE in humans. However, the long-term
side effects of their use and dosage requirements are still unknown and demand extensive in vivo
research before they can be fully supported as an adjunctive treatment for SBE. The use of structural
biology to screen and identify small molecules that are likely to affect venom toxins is also beneficial in
finding alternative treatments for SBE. In this study, the structure of CAMP-2 was modeled and used
in a docking analysis with batimastat and marimastat. Batimastat possessed higher binding energy
and inhibitory constant, whereas marimastat has formed multiple hydrogen bonds with the active site
of CAMP-2. While batimastat was found to interact with one of the catalytic triad histidine (His 154)
residues through its backbone nitrogen, marimastat was observed to form a bifurcated hydrogen bond
interaction with another active site residue, glutamate (Glu 145), through its sidechain oxygen. Due to
the easy access and robustness of these in silico approaches, they can be used to analyse the binding
efficiencies of these and other similar molecules with SVMPs from diverse venoms to determine their
potential in treating SBE.
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SVMPs play important roles in the overall pathophysiology of viper envenoming by inducing
local tissue damage and haemorrhage, which can be primarily attributed to their potential to degrade
basement membrane components and affect coagulation factors [18,40]. SVMPs activate two key
coagulation factors, factor X and prothrombin, to exhibit their procoagulant effects. SVMPs are also
known to digest plasma fibrinogen, which may induce clotting effects in some cases, but, largely,
it induces the consumption coagulopathy by reducing the functional fibrinogen levels in the plasma,
which subsequently results in bleeding. CAMP-2 has also exerted its ability to degrade fibrinogen,
specifically the Aα chain, with delayed/minimal effect on Bβ chain. SVMPs [18,40], as well as venom
serine proteases [41], show varying specificity to cleave the Aα and/or Bβ chains of fibrinogen with
rarely an effect on the γ chain. Therefore, in addition to their impact on local tissue damage, the effects
of SVMPs on the blood coagulation factors, specifically fibrinogen, should also be reduced in order to
combat SBE-induced pathological complications.
In conclusion, SVMPs are one of the key venom toxins that should be neutralised as quickly
as possible following a snakebite, particularly in the case of vipers. The inability of antivenoms to
counteract the effects of SVMPs, particularly at the local bite site, emphasises the urgent need to develop
alternative, small molecule-based treatments to minimise SBE-induced tissue damage, which often
results in permanent disabilities. In this study, we give a comprehensive analysis of the applications of
batimastat, marimastat, EDTA and ZnCl2 in inhibiting a purified PI SVMP, CAMP-2, in comparison
to the whole C. atrox venom. The cytotoxic effects of batimastat and marimastat were also analysed.
Hence, this study demonstrates a robust method to screen small molecule inhibitors for therapeutic
utility against venom toxins using a spectrum of functional assays and in silico techniques in order to
develop alternative therapies for SBE.
4. Materials and Methods
4.1. Protein Purification
Lyophilised C. atrox venom (50 mg) (Sigma Aldrich, Dorset, UK) was dissolved in 1 mL of 20 mM
Tris.HCl (pH 7.4) (ThermoScientific, Loughborough, UK), and after centrifugation at 5000× g for 5 min
to remove the undissolved materials, the supernatant was applied to a 5-mL HiTrap™ Sepharose
(SP) HP cation exchange chromatography column (GE Healthcare, Amersham, UK) and fractionated
using an Akta Purifier (GE Healthcare, Amersham, UK). Fractions were collected at a rate of 1 mL/min
using 20 mM Tris.HCl pH 7.4 (Buffer A) and 1 M NaCl prepared in Buffer A (Buffer B) with a gradient
reaching 60% Buffer B over 30 min. All fractions containing the target protein were pooled together,
desalted and concentrated using Vivaspin ultra-centrifugal filtration tubes (Sartorius, Epsom, UK),
and applied to a gel filtration column (Superdex 75) to further purify the target protein. Fractions were
collected at a rate of 1 mL/min using 20 mM Tris.HCl (pH 7.4).
The fractions were stored on ice and analysed by Bradford protein assay according to the
manufacturer’s protocol (ThermoScientific, Loughborough, UK) and SDS-PAGE, as described
previously [42]. The protein assay was run, and the intensity of the color developed was measured
at 600 nm using an Emax spectrophotometer (Molecular Devices, Wokingham, UK). Bovine serum
albumin (BSA) (ThermoScientific, Loughborough, UK) was used as a standard in the protein assay.
For SDS-PAGE, the proteins were denatured using reducing sample treatment buffer (RSTB) (10% (w/v)
SDS (ThermoScientific, Loughborough, UK), 10% (v/v) β-mercaptoethanol (Sigma Aldrich, Dorset, UK),
1% (w/v) bromophenol blue (Sigma Aldrich, Dorset, UK), 50% (v/v) glycerol (ThermoScientific,
Loughborough, UK) and 20 mM Tris.HCl (pH 7.4)) and heating at 90 ◦C for 10 min. Samples (30 µL
from each fraction) were loaded into precast gradient (4–15%) Mini-PROTEAN® TGX™ gels (Bio-Rad,
Watford, UK) alongside a protein molecular weight marker (Bio-Rad, Watford, UK) and resolved using
a Mini-Protean II apparatus (Biorad, Watford, UK). Gels were immersed in a staining solution (0.1%
(w/v) Coomassie Brilliant blue R250 (Sigma Aldrich, Dorset, UK) dissolved in 10% (v/v) acetic acid
(ThermoScientific, Loughborough, UK), 40% (v/v) methanol (ThermoScientific, Loughborough, UK)
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and 50% deionized water) for 1 h on a plate shaker, washed 3x with deionised water for 5 min and
destained (10% (v/v) acetic acid, 10% (v/v) methanol and 80% deionized water) for 3 h or until protein
bands became clear.
4.2. Mass Spectrometry Analysis
A gel slice (from SDS-PAGE) containing CAMP-2 was subjected to tryptic digestion before
undergoing mass spectrometry analysis at Alta Bioscience (Birmingham, UK), as we described
previously [14]. Both MS and MS/MS scans were cross-referenced against the Uniprot protein
database using the Sequest algorithm (Thermo fisher PD 1.4) in order to determine the identity of the
purified protein.
4.3. Fluorogenic Assays
The metalloprotease (collagenolytic) activity of the venom or the purified protein (CAMP-2)
was measured using a fluorogenic substrate, DQ™-gelatin (ThermoScientific, Loughborough, UK).
Several concentrations of the purified protein or venom (with and without different concentrations of
batimastat, marimastat, EDTA, ZnCl2 and CaCl2 (Sigma Aldrich, Dorset, UK)) were added to a black
96-well plate in triplicates along with appropriate controls. Then DQ-gelatin (10 µg/mL) was added to
each well, and following mixing, the plate was incubated at 37 ◦C and the level of fluorescence was
measured at various time points using an excitation of 485 nm and emission wavelength of 520 nm in
a FLUOstar OPTIMA (BMG Labtech, Ortenberg, Germany) spectrofluorimeter. To determine PLA2
activity, an EnzChek™ Phospholipase A2 Assay Kit (ThermoFisher Scientific, Loughborough, UK) was
used in accordance with the manufacturer’s instructions.
4.4. Fibrinogenolytic Assay
CAMP-2 (1 mg/mL) was mixed with fibrinogen (10 mg/mL) (Sigma Aldrich, Dorset, UK) in PBS
and incubated at 37 ◦C for various time points. Samples (50 µL) were taken at time intervals of 10,
30 and 60 min and then again after 12 h and immediately mixed with 25 µL of RSTB before boiling at
90 ◦C for 10 min. Each sample was then analysed by SDS-PAGE, as explained above.
4.5. Human Blood Collection, Platelet Preparation and Aggregation Assay
Blood samples from healthy human volunteers were obtained in accordance with the approved
procedures by the University of Reading Research Ethics Committee (UREC 17/17 approved: 10 May
2017) and after obtaining written informed consent. The platelets were prepared, as described
previously [42]. Blood was collected using venepuncture into vacutainers containing 3.2% (w/v) citrate.
For PRP, blood samples were centrifuged at 102× g for 20 min at 20 ◦C. PRP was rested for 30 min at
30 ◦C in a water bath before use. For isolated platelets preparation, the PRP was mixed with 3 mL of
acid citrate dextrose (ACD) and 10 ng/mL prostacyclin (PG12 dissolved in EthOH) (Sigma Aldrich,
Dorset, UK) and mixed gently by inversion and centrifuged at 1413 g. Modified tyrodes-HEPES buffer
(1 ml with 5 mM glucose) was added together with 150 µL of ACD to the platelet pellet to resuspend
the pellet, and the final volume was made up to 25 mL using a pre-warmed modified tyrodes-HEPES
buffer. A further 3 mL of ACD and 10 ng/mL prostacyclin was added prior to centrifuging at 1413× g
for 10 min at 20 ◦C. Finally, the supernatant was discarded, and the platelets were resuspended in
modified tyrodes-HEPES buffer at a density of 4 × 108 platelets/mL. The aggregation assays were
performed using isolated platelets or PRP with 0.5 µg/mL CRP-XL (obtained from Professor Richard
Farndale, University of Cambridge, UK) as an agonist. The level of aggregation in the presence and
absence of different concentrations of venom or CAMP-2 was monitored using an optical aggregometer
(model 700, Chrono-log, USA).
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4.6. Haemolytic Assay
Human erythrocytes were collected from the dense red blood cells found in the bottom of
vacutainers following centrifugation for the collection of PRP, as mentioned above. These erythrocytes
were then washed three times by mixing with an equal volume of PBS, centrifuging at 2000× g for
2 min, and discarding the supernatant. The haemolytic activity was measured using these washed
human erythrocytes suspended in calcified phosphate-buffered saline (PBS). The erythrocytes were
treated with different concentrations of CAMP-2 or venom and incubated at 37 ◦C for various time
points. A detergent, Triton X-100 (1%) (Sigma Aldrich, Dorset, UK), and PBS were used as a positive
and negative control, respectively. Following incubation, the samples were centrifuged at 2000× g
for two minutes and 50 µL of supernatant was pipetted into a 96-well plate and the absorbance was
measured at 540 nm using a spectrophotometer.
4.7. LDH Cytotoxicity Assay
An LDH cytotoxicity assay kit (ThermoFisher, Loughborough, UK) was used in accordance
with the manufacturer’s instructions. Briefly, human platelets were incubated at 37 ◦C for 30 min
prior to incubation with different concentrations of venom or CAMP-2 or small molecule inhibitors
for five minutes. These results were compared with those from the positive control (100% lysis)
achieved using the lysis buffer provided. The substrate mix from the kit was added to the platelets and
incubated for another 30 min and subsequently stopped using the stop solution provided. The level of
absorbance was read at 490 and 650 nm using a Fluostar Optima (BMG Labtech, Ortenberg, Germany)
spectrofluorimeter. The assay was performed in duplicates using platelets obtained from three
individual donors.
4.8. Structure Modelling and Molecular Docking
A three-dimensional structure of CAMP-2 was developed using homology modeling in the Swiss
Model Server [24] based on the crystal structure of adamalysin II (PDB accession number: 4AIG)
from the venom of Crotalus adamanteus as a template. Before proceeding to the docking simulation,
protein preparation steps such as fixing charge for the Zn2+ metal ion, adding solvation parameters and
polar hydrogens to the metalloprotease were carried out. AutoDock [25] necessitates pre-calculated
grid maps for each type of atom present in the ligand molecule being docked because it stores the
potential energy produced from interacting with the macromolecule. This grid surrounds the region of
interest (active site) of the macromolecule. A grid box of size 50 × 50 × 50 Å with a spacing of 0.375 Å
was prepared at the active site of CAMP-2 metalloprotease. The Lamarckian genetic algorithm was
used to identify the best conformers. Throughout the docking process, a maximum of 15 conformers
was considered per compound. AutoDock (version 4.0 SRC, California, USA) was compiled and run
under Microsoft Windows XP operating system.
4.9. Statistical Analysis
All statistical analyses were performed with GraphPad Prism (version 7.0, Graphpad Prism,
California, USA, 2018). For most of the data, the statistical significance was analysed using one-way
ANOVA, which was followed by a posthoc Tukey’s test.
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